Home IV Evaluation (HIVE): Analysis of outpatient intravenous antibiotic therapy in British Columbia

Project number: 
Approval date: 
Thursday, January 3, 2019
Principal Investigator: 
University of British Columbia (UBC)
Funding Agency: 
Doctors of BC Section of Infectious Diseases
Datasets requested: 
Income band (Statistics Canada)
Consolidation registry (Ministry of Health)
Hospital Separations (BC Ministry of Health)
Consolidation - demographic (Ministry of Health)
Deaths (BC Vital Statistics Agency)
Medical Services Plan (BC Ministry of Health)
consolidation - census geocodes
Research objective: 

Research questions:
1) How has G33655 been used to support outpatient IV therapy in BC?
2) Did the introduction of the G33655 fee code policy increase the use of outpatient IV antibiotic therapy in BC?
3) How does outpatient IV antibiotic therapy compare to in-hospital IV antibiotic therapy in terms of adverse events and healthcare costs?

1) The G33655 was used for a broad range of patients and conditions.
2) The introduction of the G33655 fee code policy was associated with an increase in the use of outpatient IV antibiotic therapy.
3) Outpatient IV antibiotic therapy is associated with fewer adverse events and lower healthcare costs compared to in-hospital IV antibiotic therapy.

Page last revised: September 2, 2019